Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid)
(Synonyms: 四氢叶酸; L-5,6,7,8-Tetrahydrofolic acid; L-Tetrahydrofolic acid; THFA) 目录号 : GC33819
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid)是维生素B9(叶酸或蝶酰-L-谷氨酸)的衍生物,在甲基四氢叶酸介导的吲哚胺甲基化过程中形成,并对甲基四氢叶酸依赖性甲基转移酶具有抑制作用,Ki值为0.1mM。
Cas No.:135-16-0
Sample solution is provided at 25 µL, 10mM.
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is a derivative of vitamin B9 (folic acid or pteroyl-L-glutamic acid) which formed during the methyltetrahydrofolic acid-mediated methylation of indoleamines and exerts an inhibitory effect on methyltetrahydrofolic acid-dependent methyltransferase with Ki value of 0.1mM[1][2]. Tetrahydrofolic acid acts as a suicide substrate of tyrosinase and reduces o-quinones generated by the enzyme in its action on substrates, such as l-tyrosine and l-DOPA (o-dopaquinone), thus inhibiting enzymatic browning[3].
In vitro, rat pheochromocytoma PC12 cells were incubated with aggregate solutions (10μL/well) for 48h. Preformed aggregates were produced by mixing 50μM αS without and with Tetrahydrofolic acid (αS: Tetrahydrofolic acid molar ratios 1:0.5, 1:1 and 1:2; equivalent to 25, 50 and 100µM) and by mixing Tetrahydrofolic acid with 25μM Aβ40 or Aβ42 in the specified molar ratios (1:1, 1:2 and 1:3; equivalent to 25, 50 and 75µM). Tetrahydrofolic acid could alleviate the cytotoxicity of αS aggregates in a dose-dependent manner and also has a similar inhibitory effect on Aβ induced cytotoxicity[4]. Adh5−/−, FancC−, FancF−/− and wild-type DT40 bone marrow cells were exposed to Tetrahydrofolic acid (0-250µM) in vitro for 4h at 37°C in sealed cryovials. The viability of these cells rapidly dropped. Tetrahydrofolic acid is cytotoxic to cells lacking the Fanconi anemia DNA repair pathways or Adh5[5].
In vivo, Tetrahydrofolic acid was intraperitoneally injected into X-irradiated ICR-JCL mice with the dose of 0.5mg or 1.5mg per animal. In the Tetrahydrofolic acid-treated groups, there observed a singificant delay of time before the first incidence of death of the animals occurred. Furthermore, the treatment with Tetrahydrofolic acid increased the final survival rate from the control level of 50% up to 70% (0.5mg group) or up to 75% (1.5mg group)[6].
References:
[1] Tjong E, Dimri M, Mohiuddin S S. Biochemistry, Tetrahydrofolate. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
[2] Lin R L, Narasimhachari N. Tetrahydrofolic acid: an inhibitor of the methyltetrahydrofolic acid-mediated methylation of indolethylamines. Biochim Biophys Acta. 1975 Apr 7;385(2):268-74.
[3] Molina F G, Muñoz-Muñoz J L, Martínez-Ortiz F, et al. Tetrahydrofolic Acid is a potent suicide substrate of mushroom tyrosinase. J Agric Food Chem. 2011 Feb 23;59(4):1383-91.
[4] Wang W Q, Wu X M, Zhang Q F, et al. Tetrahydrofolic acid accelerates amyloid fibrillization, decreases cytotoxic oligomers and suppresses their toxicity. Int J Biol Macromol. 2025 Feb:290:139041.
[5] García-Calderón C B, Bejarano-García J A, Tinoco-Gago I, et al. Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells. Cell Death Differ. 2018 Nov;25(11):1967-1979.
[6] Okazaki M, Sato F, Shikita M, Akaboshi S. Therapeutic effect of tetrahydrofolic acid in midlethally x-irradiated mice. Chem Pharm Bull (Tokyo). 1971 Jun;19(6):1173-7.
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid)是维生素B9(叶酸或蝶酰-L-谷氨酸)的衍生物,在甲基四氢叶酸介导的吲哚胺甲基化过程中形成,并对甲基四氢叶酸依赖性甲基转移酶具有抑制作用,Ki值为0.1mM[1][2]。Tetrahydrofolic acid作为酪氨酸酶的自毁底物,可减少该酶作用于L-酪氨酸和L-DOPA时生成的邻醌(如多巴醌),从而抑制酶促褐变[3]。
体外实验,大鼠嗜铬细胞瘤PC12细胞与10μL/孔聚集溶液共孵育48h。聚集物通过将50μM αS与Tetrahydrofolic acid按1:0.5、1:1、1:2摩尔比(对应25、50、100μM)混合,或将25μM Aβ40或Aβ42与Tetrahydrofolic acid按1:1、1:2、1:3摩尔比(对应25、50、75μM)混合制备。Tetrahydrofolic acid可剂量依赖性地减轻αS聚集体的细胞毒性,并对Aβ诱导的细胞毒性具有类似抑制作用[4]。将Adh5-/-、FancC⁻、FancF-/- 及野生型DT40骨髓细胞在密封冻存管中暴露于Tetrahydrofolic acid(0-250μM)4h(37℃),细胞活力快速下降;Tetrahydrofolic acid对缺乏范可尼贫血DNA修复通路或Adh5的细胞具有细胞毒性[5]。
体内实验,对X射线照射的ICR-JCL小鼠腹腔注射Tetrahydrofolic acid,剂量为0.5mg或1.5mg/只。Tetrahydrofolic acid处理组出现小鼠死亡的时间显著延迟,最终生存率由对照50%提高至70%(0.5mg组)或75%(1.5mg组)[6]。
Kinase experiment [1]: | |
Preparation Method | The activity of methyltetrahydrofolic acid-dependent methyltransferase was assayed under standard conditions with increasing concentrations of Tetrahydrofolic acid up to 2mM with increasing concentrations of methyltetrahydrofolic acid or N-methylserotonin. After incubation at 37°C for 60min, the reaction was stopped. |
Reaction Conditions | 0-2mM; 60min |
Applications | Tetrahydrofolic acid inhibited methyltetrahydrofolic acid-dependent methyltransferase. The concentration of tetrahydrofolic acid required to obtain a 50% inhibition under the standard assay condition was 0.2mM. At 2mM of Tetrahydrofolic acid, practically complete inhibition was observed. |
Cell experiment [2]: | |
Cell lines | PC12 cells |
Preparation Method | PC12 cells were incubated with aggregate solutions (10μL/well) for 48h. Preformed aggregates were produced by mixing 50μM αS without and with Tetrahydrofolic acid (αS: Tetrahydrofolic acid molar ratios 1:0.5, 1:1 and 1:2; equivalent to 25, 50 and 100µM) and by mixing Tetrahydrofolic acid with 25μM Aβ40 or Aβ42 in the specified molar ratios (1:1, 1:2 and 1:3; equivalent to 25, 50 and 75µM). |
Reaction Conditions | 25, 50, 75 and 100µM; 48h |
Applications | Tetrahydrofolic acid modification could alleviate the cytotoxicity of αS aggregates in a dose-dependent manner. When incubated with αS at different molar ratios (1:0.5, 1:1 and 1:2) Tetrahydrofolic acid increased cell viability by 15.66%, 20.71% and 28.62%, respectively. Tetrahydrofolic acid also has a similar inhibitory effect on Aβ induced cytotoxicity. When incubated with Aβ40 at different molar ratios (1:1, 1:2, and 1:3) Tetrahydrofolic acid increased cell viability by 11.20%, 20.26% and 27.52%. |
Animal experiment [3]: | |
Animal models | Male ICR-JCL mice |
Preparation Method | Five min after termination of X-irradiation, Tetrahydrofolic acid was intraperitoneally injected in the mice in the dose of 0.5mg or 1.5mg per animal. |
Dosage form | 0.5mg or 1.5mg; i.p.; a single administration |
Applications | The treatment with Tetrahydrofolic acid increased the final survival rate from the control level of 50% up to 70% (0.5mg group) or up to 75% (1.5mg group). |
References: |
Cas No. | 135-16-0 | SDF | |
别名 | 四氢叶酸; L-5,6,7,8-Tetrahydrofolic acid; L-Tetrahydrofolic acid; THFA | ||
Canonical SMILES | NC(NC1=C2NC(CNC3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)CN1)=NC2=O | ||
分子式 | C19H23N7O6 | 分子量 | 445.43 |
溶解度 | DMSO : 20.83 mg/mL (46.76 mM; Need ultrasonic) | 储存条件 | Store at -20°C; protect from light, stored under nitrogen,unstable in solution, ready to use. |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.245 mL | 11.2251 mL | 22.4502 mL |
5 mM | 0.449 mL | 2.245 mL | 4.49 mL |
10 mM | 0.2245 mL | 1.1225 mL | 2.245 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >94.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet